Arrowhead Pharmaceuticals Inc (ARWR)

INDUSTRIALS: COMMERCIAL SERVICES & SUPPLIES
SIC: PHARMACEUTICAL PREPARATIONS

225 SOUTH LAKE AVENUE PASADENA, CA 91101

Arrowhead Research seeks to commercialize pioneering, breakthrough products in nanotechnology by forming or acquiring subsidiary companies; by funding nanoscience research at universities; and through the acquisition, license and sublicense of intellectual property in the field of nanotechnology.

Data based on most recent fiscal year report
Market Cap501.215 Million Shares Outstanding74.92 Million Avg Volume1.865 Million
1-Yr BETA vs S&P TR Current Ratio3.63 Quick Ratio3.63
View SEC Filings from ARWR instead.
Q2 2019 All Institutions Hedge Funds 1
To trade ARWR now:
Filers who had this stock in their top 10: 3 2 (0.21%)
13F Filers holding this stock: 205 30 (3.1%)
Aggregate 13F shares on 06/30/2019: 68.141 Million 14.714 Million
Aggregate 13F shares on 03/31/2019: 59.044 Million 16.394 Million
Percent change: 15.41% -10.25%
Funds creating new positions: 59 3
Funds Adding to an existing position: 73 11
Funds closing out their position: 23 3
Funds reducing their position: 52 14
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ARWR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

185 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

PERRY MICHAEL S

  • Director
36,000 2019-09-09 2

MCDONNEL PAUL CLAYTON INTERIM CFO

  • Officer
0 2019-08-15 0

FERRARI MAURO

  • Director
1,900 2019-06-26 3

WADDILL WILLIAM D.

  • Director
0 2019-06-07 2

MYSZKOWSKI KENNETH ALLEN CHIEF FINANCIAL OFFICER

  • Officer
313,536 2019-05-31 5

O'BRIEN PATRICK GENERAL COUNSEL

  • Officer
203,000 2019-05-28 3

LEONE PETER BRIAN CHIEF BUSINESS OFFICER

  • Officer
0 2019-05-28 1

ANZALONE CHRISTOPHER RICHARD CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
2,141,903 2019-05-24 6

GIVEN BRUCE D CHIEF OPERATING OFFICER

  • Officer
644,606 2019-03-01 9

GIVEN DOUGLAS B

  • Director
175,130 2019-02-22 6

LI ZHEN SNR. VP, CHEM AND NON-CLIN DEV

  • Officer
201,700 2019-01-14 2

FRYKMAN EDWARD W

  • Director
148,852 2018-01-01 0

LEWIS DAVID L. CHIEF SCIENTIFIC OFFICER

  • Officer
0 2016-01-01 0

MCKENNEY CHARLES

  • Director
42,220 2015-03-04 0

RAHN LEROY T

  • Director
0 2010-03-04 0

STEWART R BRUCE EXECUTIVE CHAIRMAN

  • Officer
  • Director
0 2010-03-04 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

PERRY MICHAEL S - Director

2019-09-11 S 85,000 $30.00 d 36,000 36,000.00 direct

PERRY MICHAEL S - Director

2019-09-09 S 100,000 $28.90 d 121,000 36,000.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments